FROM PATHOLOGICAL PROCESSES TO PATHOGENESIS OF MEdICALLY ALLERGY
- Authors: Mavlyanov IR1, Ashirmetov AH1, Mavlyanov ZI1
-
Affiliations:
- Tashkent medical academy
- Issue: Vol 9, No 2 (2017)
- Pages: 19-27
- Section: Reviews
- URL: https://bakhtiniada.ru/vszgmu/article/view/8555
- DOI: https://doi.org/10.17816/mechnikov20179219-27
- ID: 8555
Cite item
Full Text
Abstract
Keywords
Full Text
##article.viewOnOriginalSite##About the authors
I R Mavlyanov
Tashkent medical academy
A H Ashirmetov
Tashkent medical academy
Z I Mavlyanov
Tashkent medical academy
References
- Pleasants RA, Walker TR, Samuelson WM. Allergic reactions to parenteral betalactam antibiotics in patients with cystic fibrosis. Chest 1994; 106: 11241128.
- Pavlos R, Phillips EJ. Individualization of antiretroviral therapy. Pharmgenomics Pers Med. 2012; 5: 117.
- Pichler WJ. Drug Hypersensitivity. Karger, Basel; 2007.
- Adam J., Pichler W.J., Yerly D. Delayed drug hypersensitivity: models of Tcell stimulation Br J ClinPharmacol. 2010; 71:5 / 701707.
- Аsensi V., Collazos J., ValleGaray E. Can antiretroviral therapy be tailored to each human immunodeficiency virusinfected individual? Role of pharmacogenomics World J Virol. 2015; 12, № 4 (3): 169177.
- Wah Fung Tse, Weimin Yang, Wenlong Huang. A narrative review of costeffectiveness analysis of people living with HIV treated with HAART: from interventions to outcomes Clinicoecon Outcomes Res. 2015; 7: 431439.
- Новиков Д.К., Сергеев Ю.В., Новиков П.Д. Лекарственная аллергия, М. 2001, 312 с.
- ElGhaiesh S, Monshi MM, Whitaker P, et al. Characterization of the antigen specificity of Tcell clones from piperacillinhypersensitive patients with cystic fibrosis. J Pharmacol ExpTher 2012; 341: 597610.
- Castrejon JL, Berry N, ElGhaiesh S, et al. Stimulation of human T cells with sulfonamides and sulfonamide metabolites. J Allergy ClinImmunol 2010; 125: 4118.e4.
- Watkins S, Pichler WJ. Sulfamethoxazole induces a switch mechanism in T cell receptors containing TCRVbeta201, altering pHLA recognition. PLoS One 2013; 8: e76211.
- Wuillemin N, Adam J, Fontana S, et al. HLA haplotype determines hapten or pi T cell reactivity to flucloxacillin. J Immunol 2013; 190: 495664.
- Monshi MM, Faulkner L, Gibson A, et al. Human leukocyte antigen (HLA)B*57:01restricted activation of drugspecific T cells provides the immunological basis for flucloxacillininduced liver injury. Hepatology 2013; 57: 72739.
- Picard D, Janela B, Descamps V, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response. SciTransl Med 2010; 2: 4662.
- Mallal S, Nolan D, Witt C, et al. Association between presence of HLAB*5701, HLADR7, and HLADQ3 and hypersensitivity to HIV1 reversetranscriptase inhibitor abacavir. Lancet 2002; 359: 727732.
- McCormack M, Alfirevic A, Bourgeois S, et al. HLAA*3101 and carbamazepineinduced hypersensitivity reactions in Europeans. N Engl J Med 2011; 364: 11341143.
- Hung SI, Chung WH, Liou LB, et al. HLAB*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. ProcNatlAcadSci USA 2005; 102: 41344139.
- Cargnin S, Jommi C, Canonico PL, et al. Diagnostic accuracy of HLAB*57: 01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a metaanalytic review. Pharmacogenomics. 2014; 15: 963976.
- Pirmohamed M, Back DJ. The pharmacogenomics of HIV therapy. Pharmacogenomics J. 2001; 1: 243253.
- Vitezica ZG, Milpied B, Lonjou C, et al. HLADRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz. AIDS 2008; 22: 540541.
- Yuan J, Guo S, Hall D, et al. Toxicogenomics of nevirapineassociated cutaneous and hepatic adverse events among populations of African,Asian, and European descent. AIDS 2011; 25: 12711280.
- Chantarangsu S, Mushiroda T, Mahasirimongkol S, et al. HLAB*3505 alleleis a strong predictor for nevirapineinduced skin adverse drug reactions inHIVinfected Thai patients. Pharmacogenet Genomics 2009; 19: 139146.
- Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapineassociated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis. 2006; 43: 783786.
- Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLADRB1*0101 and abrogated by low CD4 Tcell counts. AIDS. 2005; 19: 9799.
- Tassaneeyakul W, Tiamkao S, Jantararoungtong T, et al. Association between HLAB*1502 and carbamazepineinduced severe cutaneous adverse drug reactions in a Thai population. Epilepsia 2010; 51: 92630.
- Ding WY, Lee CK, Choon SE. Cutaneous adverse drug reactions seen in a tertiary hospital in Johor, Malaysia. Int J Dermatol 2010; 49: 83441.
- Lonjou C, Borot N, Sekula P, et al. A European study of HLAB in StevensJohnson syndrome and toxic epidermal necrolysis related to five highrisk drugs. Pharmacogenet Genomics 2008; 18: 99107.
- Ikeda H, Takahashi Y, Yamazaki E, et al. HLA class I markers in Japanese patients with carbamazepineinduced cutaneous adverse reactions. Epilepsia 2010; 51: 297300.
- Genin E, Chen DP, Hung SI, Sekula P, Schumacher M, Chang PY, et. al. HLAA* 31:01 and different types of carbamazepineinduced severe cutaneous adverse reactions: an international study and metaanalysis. Pharmacogenomics J 2014; 14: 281288.
- McCormack M, Alfirevic A, Bourgeois S, et. al. HLAA*3101 and carbamazepineinduced hypersensitivity reactionsin Europeans. N Engl J Med 2011; 364: 11341143.
- Ozeki T, Mushiroda T, Yowang A, et al. Genomewide association study identifies HLAA*3101 allele as a genetic risk factor for carbamazepineinduced cutaneous adverse drug reactions in Japanese population. Hum Mol Genet 2011; 20: 10341041.
- Lichtenfels M, Farrell J, Ogese MO, et al. HLA restriction of carbamazepinespecific TCell clones from an HLAA*31:01positive hypersensitive patient. Chem Res Toxicol 2014; 27: 175177.
- Rodriguesa R. de Oliveira, Germano P. de Carvalhoa, Gomes E.A. de Arrudac et al. Interleukin10 gene polymorphism (-1082G/A) and allergy to efavirenz in patients infected with human immunodeficiency virus Braz J infect dis. 2014; 18 (4): 445448.
- Jinno H, TanakaKagawa T, OhnoA et al. Functional characterization of cytochrome P450 2B6 allelic variants. Drug MetabDispos 2003; 31: 398403.
- Yuan J, Guo S, Hall D et al. Toxicogenomics of nevirapineassociatedcutaneous and hepatic adverse events among populations of African, Asian, and European descent. AIDS 2011; 25: 12711280.
- Sinxadi PZ, Leger PD, McIlleron HM, et al. Pharmacogenetics of plasma efavirenz exposure in HIVinfected adults and children in South Africa. Br J ClinPharmacol. 2015; 80: 146156.
- Chung WH, Chang WC, Lee YS, et al. Genetic variants associated with phenytoinrelated severe cutaneous adverse reactions. JAMA 2014; 312: 52534.
- Thornhill J., Fidler S., Frater J. Advancing the HIV cure agenda: the next 5 years. Current Opinion in Infectious Diseases. 2015; 28 (1): 19.
- Di Santo R. Inhibiting the HIV integration process: past, present, and the future. J Med Chem. 2014; 57: 539566.
- Mammen AL, Gaudet D, Brisson D, et al. Increased frequency of DRB1*11:01 in antihydroxymethylglutaryl coenzyme A reductaseassociated autoimmune myopathy. Arthritis Care Res (Hoboken) 2012; 64: 12331237.
- Goldstein JI, Jarskog LF, Hilliard C, et al. Clozapineinduced agranulocytosis is associated with rare HLADQB1 and HLAB alleles. Nat Commun 2014; 5: 4757.
- Yip VL, Marson AG, Jorgensen AL, Pirmohamed M, Alfirevic A. HLA genotype and carbamazepineinduced cutaneous adverse drug reactions: a systematic review. ClinPharmacolTher 2012; 92: 757565.
- Lonjou C, Thomas L, Borot N, et al. A marker for StevensJohnson syndrome.: ethnicity matters. Pharmacogenomics J 2006; 6: 265268.
- Mallal S, Phillips E, Carosi G, et al. HLAB*5701 screening for hypersensitivity to abacavir. N Engl J Med 2008; 358: 568579.
- Daly AK, Donaldson PT, Bhatnagar P, et al. HLAB*5701 genotype is a major determinant of druginduced liver injury due to flucloxacillin. Nat Genet 2009; 41: 816819.
- Singer JB, Lewitzky S, Leroy E, et al. A genome wide study identifies HLA alleles associated with lumiracoxibrelated liver injury. Nat Genet 2010; 42: 711714.
- Lucena MI, Molokhia M, Shen Y, et al. Susceptibility to amoxicillinclavulanateinduced liver injury is influenced by multiple HLA class I and II alleles. Gastroenterology 2011; 141: 338347.
- Hebbring SJ, Schrodi SJ, Ye Z, et al. A PheWASapproach in studying HLADRB1*1501. Genes Immun 2013; 14: 187191.
- Pirmohamed M, Park K. Mechanism of clozapineinduced agranulocytosis: current status of research and implications for drug development. CNS Drugs 1997; 7: 139158.
- Clay PG. The abacavir hypersensitivity reaction: a review. ClinTher 2002; 24: 15021514.
- Gueant JL, Romano A, CornejoGarcia JA, et al. HLADRA variants predict penicillin allergy in genomewide fine mapping genotyping. J Allergy ClinImmunol 2015; 135: 253259.
Supplementary files
